questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Éphrines
Éphrine A3
Éphrine A3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Neurodevelopmental Disorders
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Éphrine A3 : Questions médicales les plus fréquentes",
"headline": "Éphrine A3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Éphrine A3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-21",
"dateModified": "2025-02-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Éphrine A3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Éphrines",
"url": "https://questionsmedicales.fr/mesh/D036342",
"about": {
"@type": "MedicalCondition",
"name": "Éphrines",
"code": {
"@type": "MedicalCode",
"code": "D036342",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Éphrine A3",
"alternateName": "Ephrin-A3",
"code": {
"@type": "MedicalCode",
"code": "D036384",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elena B Pasquale",
"url": "https://questionsmedicales.fr/author/Elena%20B%20Pasquale",
"affiliation": {
"@type": "Organization",
"name": "Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. elenap@sbpdiscovery.org."
}
},
{
"@type": "Person",
"name": "Katsuaki Ieguchi",
"url": "https://questionsmedicales.fr/author/Katsuaki%20Ieguchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. kieguchi@twmu.ac.jp."
}
},
{
"@type": "Person",
"name": "Yoshiro Maru",
"url": "https://questionsmedicales.fr/author/Yoshiro%20Maru",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, Tokyo Women's Medical University, Tokyo, Japan. maru.yoshiro@twmu.ac.jp."
}
},
{
"@type": "Person",
"name": "Stamatios Theocharis",
"url": "https://questionsmedicales.fr/author/Stamatios%20Theocharis",
"affiliation": {
"@type": "Organization",
"name": "First Department of Pathology, Medical School, National and Kapodistrian University of Athens, 157 72 Athens, Greece."
}
},
{
"@type": "Person",
"name": "Liu Yang",
"url": "https://questionsmedicales.fr/author/Liu%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, Peking University First Hospital, Beijing, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Neurodevelopmental disorder with dystonia due to SOX6 mutations.",
"datePublished": "2022-09-07",
"url": "https://questionsmedicales.fr/article/36069193",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mgg3.2051"
}
},
{
"@type": "ScholarlyArticle",
"name": "Amblyopia treatment outcomes in patients with neurodevelopmental disorders.",
"datePublished": "2023-09-21",
"url": "https://questionsmedicales.fr/article/37739211",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jaapos.2023.07.014"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bisphenol-A and phthalate metabolism in children with neurodevelopmental disorders.",
"datePublished": "2023-09-13",
"url": "https://questionsmedicales.fr/article/37703261",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0289841"
}
},
{
"@type": "ScholarlyArticle",
"name": "LHX2 haploinsufficiency causes a variable neurodevelopmental disorder.",
"datePublished": "2023-04-11",
"url": "https://questionsmedicales.fr/article/37057675",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.gim.2023.100839"
}
},
{
"@type": "ScholarlyArticle",
"name": "Necroptosis in the developing brain: role in neurodevelopmental disorders.",
"datePublished": "2023-03-25",
"url": "https://questionsmedicales.fr/article/36964816",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11011-023-01203-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Éphrines",
"item": "https://questionsmedicales.fr/mesh/D036342"
},
{
"@type": "ListItem",
"position": 5,
"name": "Éphrine A3",
"item": "https://questionsmedicales.fr/mesh/D036384"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Éphrine A3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Éphrine A3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Éphrine A3",
"description": "Comment diagnostiquer une anomalie d'éphrine A3 ?\nQuels examens sont recommandés pour évaluer l'éphrine A3 ?\nY a-t-il des biomarqueurs associés à l'éphrine A3 ?\nQuels symptômes peuvent indiquer un problème avec l'éphrine A3 ?\nPeut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Neurodevelopmental+Disorders&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Éphrine A3",
"description": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?\nL'éphrine A3 est-elle liée à des maladies spécifiques ?\nComment l'éphrine A3 affecte-t-elle le système nerveux ?\nDes troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?\nL'éphrine A3 influence-t-elle le développement cérébral ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Neurodevelopmental+Disorders&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Éphrine A3",
"description": "Peut-on prévenir les troubles liés à l'éphrine A3 ?\nY a-t-il des facteurs environnementaux influençant l'éphrine A3 ?\nComment le mode de vie affecte-t-il l'éphrine A3 ?\nDes conseils nutritionnels peuvent-ils aider ?\nL'éducation prénatale peut-elle prévenir des troubles ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Neurodevelopmental+Disorders&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Éphrine A3",
"description": "Quels traitements ciblent l'éphrine A3 ?\nPeut-on modifier l'expression de l'éphrine A3 ?\nY a-t-il des essais cliniques sur l'éphrine A3 ?\nQuels médicaments peuvent affecter l'éphrine A3 ?\nL'éphrine A3 peut-elle être une cible thérapeutique ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Neurodevelopmental+Disorders&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Éphrine A3",
"description": "Quelles complications peuvent survenir avec l'éphrine A3 ?\nL'éphrine A3 est-elle impliquée dans des cancers ?\nDes troubles cognitifs peuvent-ils être des complications ?\nComment les complications sont-elles gérées ?\nY a-t-il des risques de récidive avec l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Neurodevelopmental+Disorders&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Éphrine A3",
"description": "Quels sont les facteurs de risque pour l'éphrine A3 ?\nL'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?\nLes toxines environnementales affectent-elles l'éphrine A3 ?\nLe stress peut-il influencer l'éphrine A3 ?\nY a-t-il des prédispositions génétiques pour l'éphrine A3 ?",
"url": "https://questionsmedicales.fr/mesh/D036384?mesh_terms=Neurodevelopmental+Disorders&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie d'éphrine A3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de tissus peuvent être utilisés pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer l'éphrine A3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunohistochimie et la PCR sont souvent utilisés pour évaluer l'expression de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à l'éphrine A3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'éphrine A3 elle-même peut servir de biomarqueur dans certaines pathologies neurologiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec l'éphrine A3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques ou des anomalies de développement peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour évaluer l'éphrine A3 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie cérébrale peut aider à visualiser des anomalies associées à des dysfonctionnements de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une dysfonction d'éphrine A3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles cognitifs, des problèmes de coordination et des retards de développement."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 est-elle liée à des maladies spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies d'éphrine A3 sont associées à des maladies neurodégénératives et des cancers."
}
},
{
"@type": "Question",
"name": "Comment l'éphrine A3 affecte-t-elle le système nerveux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle joue un rôle dans la formation des synapses et la plasticité neuronale, influençant le comportement."
}
},
{
"@type": "Question",
"name": "Des troubles comportementaux peuvent-ils être liés à l'éphrine A3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles du comportement."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 influence-t-elle le développement cérébral ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est essentielle pour le développement normal des circuits neuronaux dans le cerveau."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à l'éphrine A3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par une détection précoce et une intervention dans les cas à risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux influençant l'éphrine A3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme la nutrition et les toxines peuvent influencer son expression."
}
},
{
"@type": "Question",
"name": "Comment le mode de vie affecte-t-il l'éphrine A3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut favoriser une expression normale de l'éphrine A3 et réduire les risques."
}
},
{
"@type": "Question",
"name": "Des conseils nutritionnels peuvent-ils aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée riche en nutriments peut soutenir la santé neuronale et l'éphrine A3."
}
},
{
"@type": "Question",
"name": "L'éducation prénatale peut-elle prévenir des troubles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation prénatale sur les risques environnementaux peut aider à prévenir des troubles liés à l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent l'éphrine A3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblant les voies de signalisation peuvent être envisagés."
}
},
{
"@type": "Question",
"name": "Peut-on modifier l'expression de l'éphrine A3 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des approches pharmacologiques peuvent moduler l'expression de l'éphrine A3 dans certaines conditions."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques sur l'éphrine A3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques sont en cours pour évaluer des traitements ciblant l'éphrine A3 dans diverses pathologies."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent affecter l'éphrine A3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains médicaments anticancéreux et neuroprotecteurs peuvent influencer l'activité de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 peut-elle être une cible thérapeutique ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en raison de son rôle dans diverses maladies, elle est considérée comme une cible thérapeutique potentielle."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'éphrine A3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications neurologiques et des troubles de développement peuvent survenir en cas d'anomalies."
}
},
{
"@type": "Question",
"name": "L'éphrine A3 est-elle impliquée dans des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies d'éphrine A3 sont associées à certains types de cancers, notamment le gliome."
}
},
{
"@type": "Question",
"name": "Des troubles cognitifs peuvent-ils être des complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de l'éphrine A3 peuvent entraîner des troubles cognitifs sévères."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications implique des traitements symptomatiques et des interventions ciblées."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de récidive avec l'éphrine A3 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de récidive peuvent exister dans les cas de cancers associés à des anomalies d'éphrine A3."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'éphrine A3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs génétiques, environnementaux et le mode de vie peuvent influencer le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans les troubles d'éphrine A3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles neurologiques peuvent augmenter le risque d'anomalies."
}
},
{
"@type": "Question",
"name": "Les toxines environnementales affectent-elles l'éphrine A3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certaines toxines peut perturber l'expression de l'éphrine A3."
}
},
{
"@type": "Question",
"name": "Le stress peut-il influencer l'éphrine A3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la signalisation de l'éphrine A3 et la santé neuronale."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour l'éphrine A3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines variations génétiques peuvent prédisposer les individus à des troubles liés à l'éphrine A3."
}
}
]
}
]
}
Mutations in SOX6 have recently been recognized as a new molecular cause of neurodevelopmental disorders characterized by intellectual disability, behavioral changes, and nonspecific facial and digita...
Here we report a new case of SOX6-associated neurodegeneration and expand the phenotype to include ceratoconus. The clinical picture consisted of early onset mildly reduced intellectual function, faci...
SOX6-associated neurodevelopmental delayis ultrarare with less than 25 cases described in the literature. We report a new case who presented with early-onset mildly reduced intellectual function, faci...
To compare amblyopia treatment outcomes between patients with neurodevelopmental disorders and their typically developing peers....
Of 2,311 patients diagnosed with amblyopia between 2010 and 2014 at Boston Children's Hospital, 460 met inclusion criteria (age 2-12 with anisometropic, strabismic, or mixed amblyopia [interocular dif...
The DD group (n = 54) and TD group (n = 406) were similar in demographics, amblyogenic risk factors, baseline visual measures, prescribed therapy, and adherence (P ≥ 0.10). Between-visit follow-up tim...
Patients with DD and those with TD responded similarly to amblyopia therapy; however, follow-up intervals were longer in patients with DD and correlated with the likelihood of persistent amblyopia, su...
The etiology of autism spectrum (ASD) and Attention Deficit/Hyperactivity (ADHD) disorders are multifactorial. Epidemiological studies have shown associations with environmental pollutants, such as pl...
Detoxification of these two plasticizers is compromised in children with ASD and ADHD. Consequently, their tissues are more exposed to these two plasticizers....
We measured the efficiency of glucuronidation in three groups of children, ASD (n = 66), ADHD (n = 46) and healthy controls (CTR, n = 37). The children were recruited from the clinics of Rutgers-NJ Me...
(1) Both fold differences and metabolome analyses showed that the three groups of children were metabolically different from each other. (2) Of the 12 pathways examined, only the BPA and DEHP pathways...
ASD and ADHD are clinically and metabolically different but share a reduction in the efficiency of detoxification for both BPA and DEHP with the reductions for BPA being statistically significant....
LHX2 encodes the LIM homeobox 2 transcription factor (LHX2), which is highly expressed in brain and well conserved across species, but it has not been clearly linked to neurodevelopmental disorders (N...
Through international collaboration, we identified 19 individuals from 18 families with variable neurodevelopmental phenotypes, carrying a small chromosomal deletion, likely gene-disrupting or missens...
Affected individuals presented with developmental and/or behavioral abnormalities, autism spectrum disorder, variable intellectual disability, and microcephaly. We observed nucleolar accumulation for ...
We implicate LHX2 haploinsufficiency by deletion and likely gene-disrupting variants as causative for a variable NDD. Our findings suggest a loss-of-function mechanism also for likely pathogenic LHX2 ...
Cell death is vital to various organismal developmental processes including brain development. Apoptosis, the most recognized programmed cell death, has been linked to several developmental processes ...
Routine exome sequencing (ES) in individuals with neurodevelopmental disorders (NDD) remains inconclusive in >50% of the cases. Research analysis of unsolved cases can identify novel candidate genes b...
Cortical development consists of a series of synchronised events, including fate transition of cortical progenitors, neuronal migration, specification and connectivity. It is becoming clear that gene ...
The pre-mRNA-processing factor 8, encoded by PRPF8, is a scaffolding component of a spliceosome complex involved in the removal of introns from mRNA precursors. Previously, heterozygous pathogenic var...
Misconceptions about how the brain works (neuromyths) are shown to be common among educators, but little is known about neurodevelopmental disorders (NDDs) neuromyths. Here, we explored the prevalence...
Routine diagnostics is biased towards genes and variants with satisfactory evidence, but rare disorders with only little confirmation of their pathogenicity might be missed. Many of these genes can, h...